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OBJECTIVES: Remote ischemic perconditioning is the newest technique used to lessen ischemia/reperfusion
injury. However, its effect in hypertensive animals has not been investigated. This study aimed to examine the
effect of remote ischemic perconditioning in spontaneously hypertensive rats and determine whether chronic
treatment with Olmesartan could influence the effect of remote ischemic perconditioning.
METHODS: Sixty rats were randomly divided into six groups: vehicle-sham, vehicle-ischemia/reperfusion injury,
vehicle-remote ischemic perconditioning, olmesartan-sham, olmesartan-ischemia/reperfusion and olmesartan-
remote ischemic perconditioning. The left ventricular mass index, creatine kinase concentration, infarct size,
arrhythmia scores, HIF-1a mRNA expression, miR-21 expression and miR-210 expression were measured.
RESULTS: Olmesartan significantly reduced the left ventricular mass index, decreased the creatine kinase
concentration, limited the infarct size and reduced the arrhythmia score. The infarct size, creatine kinase
concentration and arrhythmia score during reperfusion were similar for the vehicle-ischemia/reperfusion group
and vehicle-remote ischemic perconditioning group. However, these values were significantly decreased in the
olmesartan-remote ischemic perconditioning group compared to the olmesartan-ischemia/reperfusion injury
group. HIF-1a, miR-21 and miR-210 expression were markedly down-regulated in the Olmesartan-sham group
compared to the vehicle-sham group and significantly up-regulated in the olmesartan-remote ischemic
perconditioning group compared to the olmesartan-ischemia/reperfusion injury group.
CONCLUSION: The results indicate that (1) the protective effect of remote ischemic perconditioning is lost in
vehicle-treated rats and that chronic treatment with Olmesartan restores the protective effect of remote
ischemic perconditioning; (2) chronic treatment with Olmesartan down-regulates HIF-1a, miR-21 and miR-210
expression and reduces hypertrophy, thereby limiting ischemia/reperfusion injury; and (3) recovery of the
protective effect of remote ischemic perconditioning is related to the up-regulation of HIF-1a, miR-21 and
miR-210 expression.
KEYWORDS: Olmesartan; ischemia/reperfusion injury; remote ischemic perconditioning; spontaneously
hypertensive rat.
Lu X, Bi YW, Chen KB, Olmesartan restores the protective effect of remote ischemic perconditioning against myocardial ischemia/reperfusion
injury in spontaneously hypertensive rats. Clinics. 2015;70(7):500-507
Received for publication on December 20, 2014; First review completed on March 17, 2015; Accepted for publication on May 12, 2015
E-mail: ywbi_qlyy@sina.cn
*Corresponding author
’ INTRODUCTION
Ischemia/reperfusion (I/R) injury is a widespread phenom-
enon that occurs in all clinical scenarios when the blood supply
to tissues is interrupted and then restored. The possibility of
severe I/R injury should be considered during acute arterial
occlusions, valve replacements and organ transplantations.
Therefore, reducing the degree of I/R injury has great clinical
significance. Cardioprotective strategies, such as ischemic
preconditioning (IPC) and ischemic postconditioning (IPOST),
effectively lessen I/R injury and reduce the myocardial infarct
size. Recent studies have demonstrated that brief repetitive
ischemia and reperfusion of a remote organ or limb during
target organ ischemia, termed remote ischemic perconditioning
(RIPER), could generate protection for the target organ
challenged by lethal ischemia (1). Compared to other con-
ditioning techniques used to lessen I/R injury (IPC and IPOST),DOI: 10.6061/clinics/2015(07)07
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mercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.
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RIPER is a noninvasive technique and does not prolong the
operating time.
Hypoxia occurs following acute and chronic ischemia. The
major effector of the hypoxic response in metazoan is hypoxia-
inducible factor-1 (HIF-1), a heterodimeric complex containing an
oxygen-labile a-subunit and a constitutively expressed b-subunit
(2). An increase in HIF-1a is one of the first adaptive responses of
human myocardium to myocardial ischemia or infarction (3).
Moreover, HIF-1a plays a central role in IPC-mediated and
IPOST-mediated cardioprotection (4,5).
MicroRNAs (miRs) are a class of endogenous 20–24
nucleotide non-protein-coding RNAs that regulate eukaryo-
tic gene expression at the post-transcriptional level (6).
In addition to the canonical HIF-1 regulation, a specific set
of miRs, termed hypoxamirs, play important roles in hypoxic
adaptation (7). During the past 5 years they have emerged as
regulators of I/R injury as well as IPC and IPOST (8).
Hypertension, as a common cardiovascular risk factor,
increases myocardial load/mechanical stress and may
thereby exacerbate the outcome of an I/R insult to the heart
(9). Numerous experimental studies have revealed that the
cardioprotective effects of IPC and IPOST have been
diminished or abrogated in the presence of hypertension
(10,11). However, little is known about the effects of RIPER
on infarct size in hypertensive animals.
Angiotensin II receptor blockers (ARBs) are a class of
drugs with increasing use in treating hypertension. Olme-
sartan, as a new ARB, has shown beneficial effects beyond
decreasing blood pressure (BP). Clinical studies have
demonstrated that olmesartan could reverse the remodeling
and angiosclerosis of small resistance vessels, reduce levels
of inflammatory factors, inhibit the progression of athero-
sclerosis, and reduce the risk of major adverse cardiac and
cerebrovascular events (12-14). Swindle found that compared
to other ARBs (valsartan, losartan and irbesartan), olmesar-
tan is associated with a lower risk of cardiac events and
lower healthcare resource utilization and costs (15).
Considering that most hypertensive patients undergoing
I/R injury are pretreated with antihypertension agents (such
as olmesartan) and that these agents may potentially modify
intracellular signaling relevant to cytoprotection, and thus
myocardial responses to cardioprotective strategies, the
objectives of the present study are (i) to examine the effect
of a protocol of RIPER against infarct size in spontaneously
hypertensive rats (SHRs); (ii) to determine whether chronic
treatment with Olmesartan can influence the effects of RIPER
in hypertensive rat hearts; and (iii) to examine whether HIF-
1a, miR-21 and miR-210 are involved in the protective effects
afforded by olmesartan and RIPER.
’ METHODS
Ethics
All of the rats were handled in accordance with the ‘‘Guide for
the Care and Use of Laboratory Animals’’ published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996). The experiment was approved by the Animal Care and
Use Committee of Taishan Medical University and was carried
out in the Key Laboratory of Atherosclerosis in Universities of
Shandong (Taishan Medical University).
Animal housing and surgical preparation
SHRs, aged 12 weeks, were used in this study. SHRs were
provided by Vital River Laboratories and were housed in
stainless steel cages, six to a cage, with food and water
available ad libitum and natural illumination. Sixty SHRs
were randomly divided into two groups: SHRs in the vehicle
group (n=30) were given vehicle besides normal diet for four
weeks, whereas those in the olmesartan group received
olmesartan (5 mg/kg) by stomach rearing every day along-
side a normal diet for four weeks. BP was assayed every
week.
After an intraperitoneal injection of sodium pentobarbital
(45 mg/kg), the body weight (BW) of SHRs was recorded.
Then, each rat was fixed in the supine position on an
operation platform with a heating pad (36.0-38.0 ˚C) to
maintain body temperature. The animal was tracheally
intubated and mechanically ventilated using a small animal
ventilator (Animal Respirator ALC-V8, Alcott Biotech,
Shanghai, China). The chest was opened by a left thoracot-
omy through the fourth intercostal space. After removing the
pericardium and exposing the heart, a 6-0 monofilament
suture was placed around the proximal portion of the left
anterior descending coronary artery (LAD) and passed
through a short piece of tubing (PE50) to create a reversible
snare. Following stabilization of the heart, coronary occlu-
sion was initiated by clamping the snare onto the epicardial
surface directly above the coronary artery. Successful
occlusion of LAD was confirmed by the presence of ST
segment elevation on the ECG and a change in ventricular
color from fresh red to dark red. After 40 min of occlusion,
reperfusion was achieved by loosening the snare and
confirmed by a marked hyperemic response at reperfusion.
Experimental protocol
Two groups of animals were randomly assigned to one of
three subgroups: (i) the sham subgroup (n=10), where SHRs
underwent the same surgical procedures except that the
suture passed under the LAD without being tightened; (ii)
the I/R subgroup (n=10), where the LAD of SHRs was
ligated for 40 min followed by 180 min of reperfusion and
(iii) the RIPER subgroup (n=10), where during the occlusion
of the LAD and before the reperfusion, the left hind limb of
SHRs was subject to three cycles of 5 min of ischemia
followed by 5 min of reperfusion.
Measurement of tail artery blood pressure
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured in conscious SHRs every week by tail-
cuff plethysmography (ALC-NIBP, Alcott Biotech, Shanghai,
China) before surgery. Recordings were started after
5-10 min of acclimation. Three successful measurements
were averaged as a single data point.
Measurement of ventricular arrhythmias
After a 10 min stabilization period, Heart rate (HR) was
taken as the baseline value using an MP 150 data acquisition
and analysis system (BIOPAC Systems Inc., Goleta, CA,
USA). Ventricular arrhythmias were recorded from LAD
occlusion to 3 h of reperfusion. The severity of arrhythmias
in each heart in the vehicle-I/R group, the olmesartan-I/R
group, the vehicle-RIPER group and the olmesartan-RIPER
group was quantified by a scoring system in which each
individual heart was evaluated via a five-point arrhythmia
score as previously described (16).
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Measurement of serum creatine kinase and left
ventricular mass index
At the end of reperfusion, artery blood samples were
collected from the left carotid artery. The serum creatine
kinase (CK) of samples was measured using a Creatine
Kinase Kit [NAC Method] (Kehua Bio-engineering Co., Ltd,
Shanghai, China) and TBA-120FR automatic biochemistry
analyzer (Toshiba Corporation, Tokyo, JP) according to the
manufacturer’s instructions.
After the blood samples were collected, the LAD was re-
occluded and 1 ml of 2% Evans blue dye was injected into
the right jugular vein to stain the normally perfused region of
the heart and delineate the area at risk. Then, the rat was
killed by injection of 10% potassium chloride through the
right carotid artery. The entire heart was excised and rinsed
of excess blue dye. The right ventricle and atria were
trimmed off. The weight of the left ventricle (LVW) was
measured. Then, the left ventricular mass index (LVMI) was
calculated as LVW to BW ratio (LVW/BW, mg/g).
Evaluation of the area at risk and myocardial infarct
size
The left ventricle was frozen at -80 ˚C. The frozen left
ventricle was cut into approximately six sections from the
apex to then base, and then, all tissues were incubated in a
1% solution of 2,3,5-triphe-nyltetrazolium chloride (TTC) at
37 ˚C for 15 min to differentiate necrotic (pale) from non-
necrotic (red) areas at risk. The slices were compressed
between glass plates and scanned into a computer (Epson
model G850A, Seiko Epson Corporation, Nagano, Japan).
After magnification, planimetry was carried out using image
analysis software (Image-Pro Plus 6.0, Media Cybernetics,
Rockville, MD, USA). The risk region and infarct region were
calculated from surface area analysis. After the summation of
individual slices, the area at risk (AAR) was expressed as a
percentage of the left ventricle area (AAR/LV) and the
myocardial infarct (MI) size was expressed as a percentage of
AAR (MI/AAR).
Extraction and analysis of HIF-1a and HIF-related
hypoxamirs (miR-21 and miR-210)
Total microRNA was extracted from the AAR of myocar-
dial tissue (100 mg) using a UNIQ-10 Column Trizol
Total RNA Isolation Kit (Sangon Biotech, Shanghai, China)
and reversely transcribed into cDNA using an Avian
Myeloblastosis Virus First Strand cDNA Synthesis Kit
(Sangon Biotech, Shanghai, China) according to the manu-
facturer’s instructions.
Analysis of gene expression was studied using real-time
RT-PCR with a SYBR Green PCR Master Mix (Applied
Biosystems Inc., Carlsbad, CA, USA) and the LightCycler 480
Real-Time PCR System (Roche Diagnostics Ltd., Rotkreuz,
Switzerland). The reaction program was 95 ˚C for 3 min,
followed by 40 cycles at 95 ˚C for 15 s and 60 ˚C for 40 s.
GAPDH was used as an internal control for HIF-1a and
U6 for HIF-related hypoxamirs (miR-21 and miR-210).
The primers for GAPDH, HIF-1a, U6 and HIF-related
hypoxamirs (miR-21 and miR-210) are listed in Table 1.
The relative expression levels of HIF-1a and HIF-related
hypoxamirs were analyzed by the 2-DDCT relative quantifica-
tion method (17).
Statistical analysis
Data are expressed as mean values ± SD. In experi-
ments with more than two conditions, statistical analysis
was performed using one-way analysis of variance
(ANOVA) with Dunnett’s post-hoc analysis. When only
two conditions were compared (except for the arrhythmia
score), analysis was performed by Student’s T-test.
Differences in the arrhythmia score between the groups
were compared by the Mann-Whitney U-test. All statistical
analyses were performed using SPSS version 13.0 (SPSS
Inc., Chicago, IL, USA). Po0.05 was considered statisti-
cally significant.
’ RESULTS
Chronic treatment with olmesartan reduced cardiac
hypertrophy, limited the infarct size and reduced the
severity of arrhythmias. Olmesartan reduced BP and
ameliorated left ventricular hypertrophy. Four weeks of
olmesartan treatment significantly decreased SBP, DBP and
LVMI in the olmesartan-treated SHRs (132.5±17.8 mm Hg,
97.40±17.2 mm Hg, and 2.19±0.14, respectively) compared
to the vehicle-treated SHRs (183.9±13.3 mm Hg, 130.6
±15.9 mm Hg, and 2.61±0.17, respectively) (Figure 1A).
In addition, olmesartan reduced the expression of HIF-1a,
miR-21 and miR-210. The expression levels of HIF-1a, miR-21,
and miR-210 were significantly lower in the olmesartan-sham
group than those in the vehicle-sham group (Figure 1B).
Moreover, myocardial infarct size was significantly decreased
in the olmesartan-I/R group (55.6±5.6%) compared to the
vehicle-I/R group (67.4±6.3%). Although the CK concentration
was comparable between the olmesartan-sham group and
vehicle-sham group, it was lower in the olmesartan-I/R group
Table 1 - Primers used for real-time RT-PCR.
RT primers
miR-21 5,-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAACATC-3,
miR-210 5,-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAGCCGC-3,
U6 5,-AACGCTTCACGAATTTGCGT-3,
PCR primers Forward Reverse
HIF-1a 5,-GACACGGAAACTGAAGACCAA-3, 5,-CATTAGAAGAGGGGAACATTACATC-3,
GAPDH 5,-CAAGTTCAACGGCACAGTCAA-3, 5,-CGCCAGTAGACTCCACGACA-3,
miR-21 5,-ACACTCCAGCTGGGTAGCTTATCAGACTG-3, 5,-TGGTGTCGTGGAGTCG-3,
miR-210 5,-ACACTCCAGCTGGGCTGTGCGTGTGACA-3, 5,-TGGTGTCGTGGAGTCG-3,
U6 5,-CTCGCTTCGGCAGCACA-3, 5,-AACGCTTCACGAATTTGCGT-3,
HIF-1a, hypoxia-inducible factor (HIF) -1a.
miR, microRNA.
RT-PCR, reverse transcription-polymerase chain reaction.
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(2919.9±441.6 U/l) than in the vehicle-I/R group (4574.2
±744.2 U/l) (Figure 1C).
Furthermore, olmesartan affected the severity of arrhythmias
during ischemia and reperfusion, which was evaluated via
arrhythmia score. The arrhythmia scores during ischemia and
reperfusion were 3.4±0.8 and 2.4±0.5, respectively, in the
vehicle-I/R group and 2.0±0.8 and 1.70±0.7, respectively, in the
olmesartan-I/R group (Figure 1D).
The protective effect of RIPER was abrogated in the
vehicle-treated SHRs but restored in the olmesartan-
treated SHRs. As shown in Figure 2A, the AAR was
comparable among the four groups. The infarct size was
comparable between the vehicle-I/R group and vehicle-
RIPER group, whereas it was significantly smaller in the
olmesartan-RIPER group (36.4±4.6%) than in the vehicle-I/
R, vehicle-RIPER and olmesartan-I/R groups (67.4±6.3%,
64.5±5.1%, 55.6±5.6%, respectively) (Figure 2B).
RIPER did not markedly affect the severity of arrhyth-
mias during ischemia (Figure 3A). In the vehicle-treated
SHRs, the arrhythmia score during ischemia was comparable
in the vehicle-I/R group (3.4±0.8) and vehicle-RIPER group (3.6
±0.7). In the olmesartan-treated SHRs, the arrhythmia score
during ischemia in the olmesartan-I/R group was 2.0±0.8,
which is similar to that in the olmesartan-RIPER group (2.1±0.6).
RIPER did not affect the severity of arrhythmias during
reperfusion in the vehicle-treated SHRs but reduced the
arrhythmia score during reperfusion markedly in the
olmesartan-treated SHRs (Figure 3 B). In the vehicle-
treated SHRs, the arrhythmia score during reperfusion
was comparable between the vehicle-I/R group (2.4±0.5)
and vehicle-RIPER group (2.5±0.7). In the olmesartan-
treated SHRs, the arrhythmia score in the olmesartan-I/R
group was 1.7±0.7, which was markedly attenuated to 0.6
±0.7 in the olmesartan-RIPER group.
RIPER did not have a significant influence on
CK concentration in the vehicle-treated SHRs but caused
a significant reduction in CK concentration in the
olmesartan-treated SHRs. There was no significant differ-
ence in the CK concentration between the vehicle-I/R
group (4574.2±744.2 U/l) and vehicle-RIPER group
(4,503.2±806.6 U/l) in the vehicle-treated SHRs. How-
ever, the CK concentration was significantly lower in the
Figure 1 - Effect of chronic treatment with olmesartan. (A) Olmesartan markedly reduced the left ventricular mass index. *po0.001
Olmesartan-treated SHRs versus vehicle-treated SHRs. (B) Olmesartan significantly decreased the expression of HIF-1a, miR-21 and miR-
210. *po0.001 Olmesartan-sham group versus vehicle-sham group. (C) Olmesartan markedly reduced the serum CK concentration in
SHRs with I/R injury. NS, p=0.168 Olmesartan-sham group versus vehicle-sham group. *po0.001 Olmesartan-I/R group versus vehicle-I/R
group. (D) Olmesartan markedly decreased the arrhythmia score during ischemia and reperfusion. *po0.05 Olmesartan-I/R group
versus vehicle-I/R group. CK, creatine kinase; HIF-1a, hypoxia-inducible factor-1a; I/R, ischemia/reperfusion; miR, microRNA; SHRs,
spontaneously hypertensive rats.
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olmesartan-RIPER group (1,710.3±252.9 U/l) than in the
olmesartan-I/R group (2,919.9±441.6 U/l) in the olme-
sartan-treated SHRs (Figure 4A).
I/R injury caused significant up-regulation in the mRNA
expression level of HIF-1a and significant down-regulation in
the expression level of miR-21 and miR-210. In the olmesar-
tan-treated SHRs, the expression level of HIF-1a was
significantly increased in the olmesartan-RIPER group com-
pared to the olmesartan-I/R group (Figure 4B). The expres-
sion levels of miR-21 and miR-210 were also up-regulated in
the olmesartan-RIPER group compared to the olmesartan-I/R
group in the olmesartan-treated SHRs (Figures 4C and 4D).
In the vehicle-treated SHRs, the expression level of HIF-1a
was significantly down-regulated in the vehicle-RIPER group
compared to the vehicle-I/R group. Specifically, the expres-
sion level of HIF-1a was comparable between the vehicle-
sham group and vehicle-RIPER group. The expression level of
miR-21 in the vehicle-RIPER group is similar to that in the
vehicle-I/R group. The expression level of miR-210 is
significantly lower in the vehicle-RIPER group than in the
vehicle-I/R group.
’ DISCUSSION
In this study, we demonstrate that (i) the protective effect of
RIPER was lost in SHRs and chronic treatment with
olmesartan restored the protective effect of RIPER in SHRs;
(ii) chronic treatment with olmesartan reduced I/R injury in
SHRs and RIPER further reduced I/R injury in olmesartan-
treated SHRs; and (iii) HIF-1a, miR-21 and miR-210 were
involved in the protection provided by olmesartan and RIPER.
Cardiac hypertrophy occurring in response to hypertension
is an independent and major risk factor for cardiovascular
Figure 3 - Effect of RIPER on arrhythmia scores during ischemia and reperfusion. (A) RIPER had no effect on the severity of arrhythmias
during ischemia. NS p40.05 RIPER group versus I/R group. (B) RIPER had no effect on the severity of arrhythmias during reperfusion in
vehicle-treated SHRs but significantly reduced the severity of arrhythmias during reperfusion in olmesartan-treated SHRs. NS p=0.796
Vehicle-RIPER group versus vehicle-I/R group. *po0.01 Olmesartan-RIPER group versus Olmesartan-I/R group. I/R, ischemia reperfusion;
RIPER, remote ischemic perconditioning; SHR, spontaneously hypertensive rat.
Figure 2 - Effect of chronic treatment with olmesartan and RIPER on the area at risk and infarct size. (A) Area at risk, expressed as a
percentage of left ventricle area, was comparable among the four groups. (B) Infarct size, expressed as a percentage of area at risk, was
significantly lower in the olmesartan-treated SHRs. NS p=0.286 Vehicle-RIPER group versus vehicle-I/R group. # po0.001 Olmesartan-I/R
group versus vehicle-I/R group. *po0.001 Olmesartan-RIPER group versus Olmesartan-I/R group. I/R, ischemia reperfusion; RIPER,
remote ischemic perconditioning; SHR, spontaneously hypertensive rat.
504
Olmesartan and remote perconditioning
Lu X et al.
CLINICS 2015;70(7):500-507
morbidity and mortality (18). In SHRs, increased oxidative
stress characterized by increased ROS-generating capacity
contributes to the overexpression of HIF-1a, which may be
protective during the stage of compensatory hypertrophy but
may eventually contribute to the pathology of end-stage
failure (19). In addition, miR-210, a hypoxia-specific micro-
RNA induced by HIF-1a, has been found to be a key factor
regulating HIF-dependent control of the Pasteur effect via its
repression of mitochondrial metabolism in multiple cell types
exposed to hypoxia (20). Moreover, miR-21, a highly
expressed microRNA in the cardiovascular system, is up-
regulated in the heart during pathological hypertrophy (21).
In our experiment, four weeks of olmesartan treatment
significantly reduced left ventricular hypertrophy. The
expression of HIF-1a, miR-21 and miR-210 was significantly
reduced in the olmesartan-sham group compared to the
vehicle-sham group. The result indicated that olmesartan
reduced oxidative stress by inhibiting the AT1 receptor, thereby
reducing the expression of HIF-1a, miR-210 and miR-21. Fu
demonstrated that olmesartan attenuated cardiac hypertrophy
in SHRs via the calcineurin pathway (22), whereas our study
proved that the beneficial effect of olmesartan on reducing
cardiac hypertrophy was due to the down-regulation of
expression of HIF-1a, miR-210, and miR-21.
I/R injury is a pathophysiologic process whereby hypoxic
tissue damage is accentuated following restoration of the
blood supply. Hypertrophied myocardium is at a greater risk
of sustaining injury and electrophysiological disturbances
after I/R (23). In our experiment, four weeks of olmesartan
treatment significantly reduced the serum CK concentration,
attenuated the severity of arrhythmias and limited the
infarct size in the olmesartan-I/R group compared to the
vehicle-I/R group. Dai et al. (24) reported that acute treat-
ment with olmesartan given at 5 min before the reperfusion
Figure 4 - Effect of RIPER on SHRs with I/R injury. (A) I/R injury led to a significant increase in the serum CK concentration. RIPER
markedly decreased the serum CK concentration in olmesartan-treated SHRs, whereas the serum CK concentration is similar for vehicle-
treated SHRs. *po0.001 versus sham group. #po0.001 versus I/R group. NS p=0.996 versus I/R group. (B) I/R injury significantly increased
HIF-1a expression. Compared to the vehicle-I/R group, HIF-1a expression was significantly decreased in the vehicle-RIPER group.
Compared to the olmesartan-I/R group, HIF-1a expression was significantly increased in the olmesartan-RIPER group. *po0.001 versus
sham group. NS p=0.585 versus sham group. #po0.001 versus I/R group. (C) I/R injury markedly down-regulated miR-21 expression. miR-
21 expression was comparable between the vehicle-I/R group and vehicle-RIPER group, whereas it was significantly up-regulated in the
olmesartan-RIPER group compared to the olmesartan-I/R group. *po0.01 versus sham group. #po0.001 versus I/R group. NS p=0.886
versus I/R group. (D) I/R injury significantly down-regulated miR-210 expression. miR-210 expression was significantly down-regulated
in the vehicle-RIPER group compared to the vehicle-I/R group, whereas it was significantly up-regulated in the olmesartan-RIPER group
compared to the olmesartan-I/R group. *po0.001 versus sham group. #po0.01 versus I/R group. HIF-1a, hypoxia-inducible factor-1a;
I/R, ischemia reperfusion; miR, microRNA; RIPER, remote ischemic perconditioning; SHR, spontaneously hypertensive rat.
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significantly reduced the myocardial infarct size and
improved left ventricular contractility; this result may be
related to the vasodilating effect observed with the higher
dose of olmesartan with subsequent decrease in oxygen
demand. In our experiment, we proved that olmesartan
benefited I/R myocardium in SHRs by ameliorating left
ventricular hypertrophy.
RIPER was first reported in the experimental studies of
Schmidt et al. (1) and later in the clinical studies of Botker et
al. (25). Schmidt et al. (1) proved that intermittent limb
ischemia during myocardial ischemia reduced the myocar-
dial infarct size, preserved the global systolic and diastolic
functions, and protected against arrhythmia during the
reperfusion phase through a KATP channel-dependent
mechanism. In our experiment, the protection afforded by
RIPER was abrogated in vehicle-treated SHRs. The myocar-
dial infarct size, serum CK concentration and severity of
arrhythmias were comparable between the vehicle-I/R
group and vehicle-RIPER group.
However, chronic treatment with olmesartan restored the
protective effect of RIPER in olmesartan-treated SHRs. The
myocardial infarct size and serum CK concentration were
significantly lower in the olmesartan-RIPER group than in
the olmesartan-I/R group. Although the arrhythmia score
during ischemia was comparable between the olmesartan-
RIPER group and olmesartan-I/R group, the arrhythmia
score during reperfusion was significantly lower in the
olmesartan-RIPER group than in the olmesartan-I/R group.
Compared to the olmesartan-I/R group, RIPER increased
the expression of HIF-1a in the olmesartan-RIPER group.
Activation of HIF-1a and its downstream target genes,
including erythropoietin, hemeoxygenase-1, adiponectin and
inducible nitric oxide synthase, during ischemia is associated
with improved myocardial tolerance to acute I/R injury (26).
Studies have also demonstrated that HIF-1a is involved in
cardioprotection by IPC (4) and IPOST (5). Our study
demonstrates that four weeks of olmesartan treatment
changes the effect of RIPER on HIF-1a mRNA expression;
the recovery of the effect of RIPER may be partially due to
the up-regulation of HIF-1a.
miR-210 and miR-21 are two HIF-1a related hypoxamirs
that have emerged as regulators of I/R injury. miR-210, as
the master hypoxamir, regulates several angiogenic factors,
inhibits caspase activity and protects against apoptosis in
both primary and transformed cells (27). Furthermore, the
down-regulation of miR-210 increases ROS levels after
hypoxia-reoxygenation (28). In our experiment, the expres-
sion of miR-210 was up-regulated in the olmesartan-RIPER
group compared to the olmesartan-I/R group. Kim found
that miR-210 is a regulator of the cytoprotection afforded by
IPC in stem cells (29), whereas our experiment shows that the
recovery of the protective effect of RIPER may be partially
due to the up-regulation of miR-210. miR-21 is also a critical
regulator of cell apoptosis. By targeting the Fas ligand (30)
and programmed cell death 4 (31), exogenous miR-21
assumes a powerful anti-apoptotic function. Specifically,
miR-21 is acutely reduced within the ischemic region during
ischemia, where replenishing it reduces the infarct size (32).
Our experiment shows that the expression of miR-21 was up-
regulated in the olmesartan-RIPER group compared to the
olmesartan-I/R group. Tu (33) demonstrated that miR-21
was remarkably up-regulated in mouse hearts after IPOST,
and the protection provide by IPOST may be related to the
anti-apoptotic role of miR-21. Our experiment demonstrates
that the recovery of the protection afforded by RIPER may be
partially due to the up-regulation of miR-21.
We demonstrate for the first time that the protective effect
of RIPER is lost in vehicle-treated SHRs and that chronic
treatment with olmesartan restores the protective effect of
RIPER in SHRs. Moreover, chronic treatment with olmesar-
tan down-regulates the expression of HIF-1a, miR-21, and
miR-210 and thereby reduces left ventricular hypertrophy.
Due to the ameliorated hypertrophy, olmesartan reduces the
CK concentration, limits the infarct size and decreases the
severity of arrhythmias in SHRs with I/R injury. Further-
more, RIPER further reduces the CK concentration, reduces
the infarct size and decreases the severity of arrhythmias
during reperfusion after chronic treatment with olmesartan.
Chronic olmesartan treatment changes the effect of RIPER on
HIF-1a, miR-21 and miR-210 expression. The recovery of the
protective effect of RIPER may be related to the up-
regulation of the expression of HIF-1a, miR-21 and miR-210.
Compared to other conditioning techniques, RIPER is a
noninvasive procedure and does not prolong the operating
time. However, the protective effect of this easy-to-use, low-risk
procedure is abrogated in SHRs. Systemic hypertension is a
common disorder worldwide. Hypertension-related clinical
sequels, such as ischemic heart disease and myocardial
infarction, continue to present pressing challenges to the
healthcare system. Olmesartan is a new ARB that is increas-
ingly used to treat hypertension. Our study demonstrates that
chronic treatment with olmesartan not only reduces I/R injury
but also restores the protective effect of RIPER in SHRs.
Therefore, olmesartan may provide a greater long-term benefit
for hypertensive patients with coronary artery disease.
Our experiment has demonstrated that chronic olmesartan
treatment changes the effect of RIPER on the expression of
HIF-1a, miR-21 and miR-210. The recovery of the protective
effect of RIPER may be related to up-regulation of the
expression of HIF-1a, miR-21 and miR-210. However,
whether RIPER can directly up-regulate the expression of
HIF-1a, miR-21 and miR-210 remains unclear. Future
research should attempt to determine whether up-regulation
of the expression of HIF-1a, miR-21 and miR-210 is required
for the protective effect afforded by RIPER.
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